AEye, Inc. Files S-1 Registration Statement
Ticker: LIDRW · Form: S-1 · Filed: Jan 16, 2025 · CIK: 1818644
Sentiment: neutral
Topics: s-1, registration-statement, sec-filing
TL;DR
AEye filed an S-1, get ready for a potential stock offering.
AI Summary
AEye, Inc. filed an S-1 registration statement on January 16, 2025, to register securities. The company, formerly known as CF Finance Acquisition Corp. III, is incorporated in Delaware and operates in the motor vehicle parts and accessories sector. Its principal executive offices are located at 4670 Willow Road, Suite 125, Pleasanton, CA 94588.
Why It Matters
This S-1 filing indicates AEye, Inc. is preparing to offer securities to the public, which could impact its capital structure and future growth prospects.
Risk Assessment
Risk Level: medium — As an S-1 filing, it signifies a potential public offering, which carries inherent market and execution risks for the company and investors.
Key Numbers
- 333-284323 — SEC File Number (Identifies the specific SEC filing)
- 3714 — SIC Code (Industry classification for Motor Vehicle Parts & Accessories)
Key Players & Entities
- AEye, Inc. (company) — Registrant
- CF Finance Acquisition Corp. III (company) — Former company name
- January 16, 2025 (date) — Filing date
- 4670 Willow Road, Suite 125, Pleasanton, CA 94588 (address) — Principal executive offices
- Matthew Fisch (person) — Chief Executive Officer
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public.
When was this S-1 filing submitted?
The S-1 filing was submitted on January 16, 2025.
What is AEye, Inc.'s former name?
AEye, Inc. was formerly known as CF Finance Acquisition Corp. III.
Where are AEye, Inc.'s principal executive offices located?
AEye, Inc.'s principal executive offices are located at 4670 Willow Road, Suite 125, Pleasanton, CA 94588.
Who is the Chief Executive Officer of AEye, Inc.?
Matthew Fisch is the Chief Executive Officer of AEye, Inc.
Filing Stats: 4,466 words · 18 min read · ~15 pages · Grade level 17.1 · Accepted 2025-01-16 17:18:15
Key Financial Figures
- $0.0001 — 0 shares of our common stock, par value $0.0001 per share (the "Common Stock") by certa
- $1.28 — e closing price of our Common Stock was $1.28 per share. 3 _______________________
Filing Documents
- ss4342875_s1.htm (S-1) — 297KB
- ss4342875_ex0501.htm (EX-5.1) — 15KB
- ss4342875_ex2301.htm (EX-23.1) — 3KB
- ss4342875_ex107.htm (EX-FILING FEES) — 18KB
- image_001.jpg (GRAPHIC) — 5KB
- 0000947871-25-000056.txt ( ) — 341KB
USE OF PROCEEDS
USE OF PROCEEDS 15 PRIVATE PLACEMENTS 16 SELLING STOCKHOLDERS 19
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 22 PLAN OF DISTRIBUTION 24 LEGAL MATTERS 26 EXPERTS 26 WHERE YOU CAN FIND MORE INFORMATION 27 Information Incorporated by Reference 28 5 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a "shelf" registration process. Under the shelf registration process, the Selling Stockholders may, from time to time, offer and sell the shares described in this prospectus in one or more offerings. Information about the Selling Stockholders may change over time. We will not receive any of the proceeds from the sale of our Common Stock by the Selling Stockholders under this prospectus. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment may also add, update, or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the heading " Where You Can Find More Information " and " Information Incorporated by Reference. " Neither we nor the Selling Stockholders have authorized anyone to provide you with any information or to make any representations other than those contained in or incorporated by reference into this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the Se